GlassScriptPhysician profile
Matthew Janowicz
NPI 1558735878
$5,945.26
in general payments reported to CMS, 2019-2025
27 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $231 · 2023: $1,391 · 2024: $2,026 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,957 · Education: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,957.16 |
| Education | $651.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $853.21 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $683.40 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $639.22 | 2023-2025 | |
| Galderma Laboratories, L.P. | $441.87 | 2024-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $394.05 | 2023-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $379.28 | 2021-2025 | |
| Pfizer INC. | $349.72 | 2023-2025 | |
| Incyte Corporation | $261.82 | 2023-2025 | Opzelura |
| Ucb, INC. | $261.13 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $259.16 | 2024-2025 | Sotyktu |
| Amgen INC. | $190.32 | 2023-2024 | Otezla, Enbrel |
| Lilly USA, LLC | $181.35 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $148.64 | 2023-2024 | Vtama |
| Almirall LLC | $148.33 | 2023-2025 | Klisyri |
| Leo Pharma INC. | $129.90 | 2023-2025 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $126.63 | 2024-2025 | |
| Organogenesis INC. | $91.87 | 2023-2025 | Puraply, Novachor |
| Biofrontera INC. | $78.43 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.91 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.13 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Arcutis Biotherapeutics, INC. | $45.80 | 2023-2024 | Zoryve |
| Organon LLC | $45.24 | 2025 | Vtama |
| Kerecis Limited | $35.33 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Verrica Pharmaceuticals INC. | $34.50 | 2023-2025 | Ycanth |
| Convatec INC. | $27.90 | 2025 | |
| Genentech USA, INC. | $20.73 | 2023 | Xolair |
| Strata Skin Sciences, INC. | $15.39 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Janowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.